JP2016088926A5 - - Google Patents

Download PDF

Info

Publication number
JP2016088926A5
JP2016088926A5 JP2015043590A JP2015043590A JP2016088926A5 JP 2016088926 A5 JP2016088926 A5 JP 2016088926A5 JP 2015043590 A JP2015043590 A JP 2015043590A JP 2015043590 A JP2015043590 A JP 2015043590A JP 2016088926 A5 JP2016088926 A5 JP 2016088926A5
Authority
JP
Japan
Prior art keywords
ikaros
inflammatory
substance
test substance
inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015043590A
Other languages
English (en)
Japanese (ja)
Other versions
JP6653120B2 (ja
JP2016088926A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016088926A publication Critical patent/JP2016088926A/ja
Publication of JP2016088926A5 publication Critical patent/JP2016088926A5/ja
Application granted granted Critical
Publication of JP6653120B2 publication Critical patent/JP6653120B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015043590A 2014-10-31 2015-03-05 Ikaros阻害に基づく抗炎症薬 Active JP6653120B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014223295 2014-10-31
JP2014223295 2014-10-31

Publications (3)

Publication Number Publication Date
JP2016088926A JP2016088926A (ja) 2016-05-23
JP2016088926A5 true JP2016088926A5 (https=) 2018-03-22
JP6653120B2 JP6653120B2 (ja) 2020-02-26

Family

ID=56017549

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015043590A Active JP6653120B2 (ja) 2014-10-31 2015-03-05 Ikaros阻害に基づく抗炎症薬

Country Status (1)

Country Link
JP (1) JP6653120B2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3797772T3 (pl) * 2019-09-03 2024-05-06 Square Power Ltd Rebamipid do zastosowania w zapobieganiu i leczeniu choroby Leśniowskiego-Crohna
CN111961702A (zh) * 2020-07-22 2020-11-20 上海珈蓓生物科技有限公司 植提物抗皮肤感染性炎症反应的细胞学评价方法及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0625159B1 (en) * 1992-09-14 2003-03-26 The General Hospital Corporation Ikaros: a regulatory gene involved in t-cell differentiation
JPH1029942A (ja) * 1996-04-02 1998-02-03 Yoichi Ichikawa 慢性関節リウマチ治療剤
US9284297B2 (en) * 2008-08-11 2016-03-15 President And Fellows Of Harvard College Halofuginone analogs for inhibition of tRNA synthetases and uses thereof
ES2872967T3 (es) * 2012-06-29 2021-11-03 Celgene Corp Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS)
US10272117B2 (en) * 2014-02-24 2019-04-30 Celgene Corporation Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders

Similar Documents

Publication Publication Date Title
Wang et al. The senescence-associated secretory phenotype and its physiological and pathological implications
Liang et al. Hyaluronan as a therapeutic target in human diseases
Locati et al. Macrophage activation and polarization as an adaptive component of innate immunity
EA201201640A1 (ru) Способы определения устойчивости рака к ингибиторам гистондеацетилазы
JP2019518063A5 (https=)
Ward et al. Plasma microRNA profiles distinguish lethal injury in acetaminophen toxicity: a research study
Shen et al. Ethyl pyruvate pretreatment attenuates concanavalin a-induced autoimmune hepatitis in mice
Manresa et al. Hydroxylase inhibition regulates inflammation-induced intestinal fibrosis through the suppression of ERK-mediated TGF-β1 signaling
Kwak et al. Quantitative evaluation of therapeutic effect of Liriope platyphylla on phthalic anhydride-induced atopic dermatitis in IL-4/Luc/CNS-1 Tg mice
JP2016528914A5 (https=)
IL272949B2 (en) Improved treatment of atopic dermatitis with tradipitant
JP2016088926A5 (https=)
Caselli Inflammation in cardiac disease: focus on Interleukin-33/ST2 pathway
RU2018104707A (ru) ИСПОЛЬЗОВАНИЕ МОЛЕКУЛЯРНЫХ МАРКЕРОВ IL-3, IL-33 и IL12ρ40 ДЛЯ ХАРАКТЕРИСТИКИ СТЕПЕНИ ТЯЖЕСТИ РЕСПИРАТОРНЫХ ИНФЕКЦИЙ, ВЫЗВАННЫХ РЕСПИРАТОРНО-СИНЦИТИАЛЬНЫМ ВИРУСОМ ЧЕЛОВЕКА И МЕТАПНЕВМОВИРУСОМ ЧЕЛОВЕКА
Xin et al. Circulating cell-free DNA indicates M1/M2 responses during septic peritonitis
Mahmutovic-Persson et al. Capacity of capsazepinoids to relax human small airways and inhibit TLR3-induced TSLP and IFNβ production in diseased bronchial epithelial cells
JP2015194481A5 (https=)
Yousefi et al. Pirfenidone downregulates eIF6, P311, and TGF-β expression and improves liver fibrosis induced by bile duct ligation in Wistar rats: evidence for liver regeneration
JP2016511822A5 (https=)
WO2014139884A3 (en) Molecular targets and inhibitors of said targets, useful in the treatment of fibrosis
Wang et al. Interaction between interleukin‑6 and angiotensin II receptor 1 in the hypothalamic paraventricular nucleus contributes to progression of heart failure
Yogarajah et al. Increased peroxisome proliferator‑activated receptor γ expression levels in visceral adipose tissue, and serum CCL2 and interleukin-6 levels during visceral adipose tissue accumulation
JP2014208601A5 (https=)
RU2017139718A (ru) Агент, индуцирующий клеточную гибель, для клеток, имеющих мутации гена braf, агент, подавляющий рост для таких клеток, и фармацевтическая композиция для терапии заболеваний, вызванных дефектом роста таких клеток
Jiang et al. CYLD-mediated DNA damage coordinates pathological cardiac hypertrophy via RIPK1-dependent signaling